Pfizer and biontech receive u.s. fda approval for 2023-2024 covid-19 vaccine

New york & mainz, germany--(business wire)--pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced that the u.s. food and drug administration (fda) approved the supplemental biologics license application (comirnaty 2023-2024 formulation) for individuals 12 years and older and granted emergency use authorization for individuals 6 months through 11 years of age for the companies' omicron xbb.1.5-adapted monovalent covid-19 vaccine. this season's vaccine is indicated as a single do.
BNTX Ratings Summary
BNTX Quant Ranking